Methylprednisolone

證據等級: L5

預測適應症: 10 個

Methylprednisolone: From Inflammatory/Autoimmune Conditions to Alopecia Areata

One-Sentence Summary

Methylprednisolone is a potent synthetic glucocorticoid used broadly for its anti-inflammatory and immunosuppressive effects across a wide range of autoimmune and inflammatory conditions. The TxGNN model predicts it may be effective for Alopecia Areata (AA), with 18 clinical trials and 20 publications retrieved in support of this direction — many of which directly evaluate methylprednisolone pulse therapy in AA patients.

Quick Overview

Item	Content
Original Indication	No Philippines registration data available (drug not registered in the Philippines)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.99%
Evidence Level	L3
Philippines Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Methylprednisolone is a synthetic glucocorticoid that binds the glucocorticoid receptor (GR) and suppresses the NF-κB signalling pathway. This reduces production of pro-inflammatory cytokines — including IL-2, IL-4, IFN-γ, and TNF-α — and directly inhibits CD4⁺ and CD8⁺ T cell activation and proliferation. The net effect is broad immunosuppression with potent anti-inflammatory activity.

Alopecia Areata is an organ-specific autoimmune disease in which CD8⁺ NKG2D⁺ T cells breach the immune privilege of the hair follicle, triggering inflammatory infiltration and arresting the hair growth cycle. The pathological mechanism is directly driven by T cell activation and the cytokine milieu methylprednisolone is designed to suppress. This mechanistic alignment explains why corticosteroids — and methylprednisolone in particular — have been used in clinical practice for decades as a systemic treatment option for moderate-to-severe and therapy-resistant AA.

In practice, methylprednisolone is administered as “pulse therapy” (high-dose intravenous bolus or oral mega-pulse regimens) to achieve peak immunosuppression while limiting cumulative steroid toxicity. Multiple retrospective cohorts, open prospective studies, systematic reviews, and at least one completed Phase 4 trial (NCT01167946) document this approach in severe AA, including alopecia totalis and alopecia universalis. The TxGNN prediction is therefore mechanistically sound and supported by an established body of clinical evidence.

Clinical Trial Evidence

Note: Many of the 18 retrieved trials are about systemic lupus erythematosus (SLE) — a condition where alopecia is a common symptom — rather than alopecia areata specifically. The table below prioritises the trials most directly relevant to methylprednisolone or corticosteroids in alopecia areata.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01167946	Phase 4	Completed	42	Oral mega-pulse methylprednisolone in severe, therapy-resistant alopecia areata (including totalis and universalis subtypes). Evaluated higher doses and more frequent pulses than conventional protocols.
NCT01017510	Phase N/A	Unknown	20	Compared DERMOJET (needle-free) vs. conventional syringe for intralesional corticosteroid injection in alopecia areata. Addresses delivery method for lesion-directed steroid therapy.
NCT07101471	N/A	Completed	296	Observational safety and effectiveness study of tofacitinib in alopecia, with some participants receiving adjuvant prednisolone. Provides real-world data on steroid co-administration in alopecia.
NCT05162586	Phase 2	Completed	456	Dose-ranging study of enpatoran in SLE and cutaneous lupus; standard-of-care background included corticosteroids. Provides disease-context and endpoint data for autoimmune hair-loss conditions.
NCT06759519	N/A	Completed	621	Multicentre retrospective-prospective observational study of active moderate-to-severe SLE in Russia. Real-world treatment patterns likely include corticosteroid use.
NCT04835441	Phase 2	Completed	76	Acazicolcept (ALPN-101) in moderate-to-severe SLE; background steroid use documented. Indirect relevance as autoimmune disease context.
NCT03843125	Phase 3	Terminated	1,147	Long-term baricitinib (JAK inhibitor) in SLE. Terminated. Illustrates the therapeutic landscape in autoimmune disease where steroids serve as backbone therapy.
NCT03616964	Phase 3	Completed	778	Baricitinib vs. placebo in SLE; corticosteroid background therapy documented. Contextual data on steroid use patterns.
NCT04582136	Phase 3	Active, not recruiting	146	Sirolimus added to standard therapy (including corticosteroids) in active SLE. Background methylprednisolone use likely documented.
NCT02031822	Phase N/A	Completed	40	Ultrasound-guided greater occipital nerve steroid injection for refractory primary headache. Demonstrates corticosteroid administration techniques relevant to nerve block contexts.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37992355	2023	Review	Dermatology Practical & Conceptual	Comprehensive review of corticosteroid pulse therapy in AA: summarises efficacy, relapse rates, adverse effects, and prognostic factors across multiple pulse regimens.
35986630	2022	Retrospective Cohort	Dermatologic Therapy	Directly compared methylprednisolone (MP) alone vs. MP + methotrexate in 26 patients with extensive AA; evaluated whether combination is superior to MP monotherapy.
32270396	2020	Systematic Review	Dermatology and Therapy	Systematic review of cyclosporine with and without systemic corticosteroids in AA; quantifies outcomes for corticosteroid-containing regimens.
25566921	2015	Clinical Study	Indian J Dermatol Venereol Leprol	IV methylprednisolone pulse in severe AA; evaluated response rates and durability in therapy-resistant cases.
18608727	2008	Clinical Study	J Dermatological Treatment	Combination of cyclosporine and methylprednisolone in severe chronic AA; addresses the high recurrence after cyclosporine monotherapy by adding MP.
30745958	2019	Clinical Study	Open Access Macedonian J Medical Sciences	Vietnamese experience with methotrexate + mini-pulse methylprednisolone in severe AA totalis/universalis; demonstrates efficacy in a resource-limited setting.
22426909	2012	Clinical Study	Saudi Medical Journal	Intensive oral mega-pulse methylprednisolone regimen in severe forms of AA; evaluated higher doses and more frequent pulses than prior protocols.
36865845	2022	Retrospective Study + Review	Indian Journal of Dermatology	Examined sex-based differences in AA outcomes following steroid pulse therapy; identifies prognostic subgroups for response.
36461625	2023	Clinical Review	Pediatric Dermatology	Reviewed pulse-dose corticosteroid therapy dosing in children with AA; highlights dosing regimen variability and associated side effects in the paediatric population.
9777767	1998	Prospective Study	J American Academy of Dermatology	Open prospective study of 45 patients receiving IV methylprednisolone pulse for severe AA; evaluated benefit in patients with ongoing hair loss of < 12 months’ duration.

Philippines Market Information

Methylprednisolone is not currently registered in the Philippines Food and Drug Administration (FDA) database. No active licenses were retrieved.

Item	Detail
Registration Status	No active Philippines FDA registrations found
Total Licenses	0

⚠️ This data gap should be verified directly with the Philippines FDA (FDA.gov.ph) before drawing conclusions, as methylprednisolone is a globally available generic medicine and may be marketed under brand names or as a hospital-use product not captured in this query.

Safety Considerations

Detailed safety data (package insert warnings, contraindications, and drug interactions) for the Philippines market were not available in this dataset.

Please refer to the package insert for safety information.

As a general clinical note, methylprednisolone pulse therapy carries established risks including transient hyperglycaemia, hypertension, insomnia, mood disturbance, hypothalamic-pituitary-adrenal (HPA) axis suppression, and in high cumulative doses, avascular necrosis, osteoporosis, and opportunistic infection. Patient selection and monitoring protocols are critical when using this regimen for AA.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Methylprednisolone pulse therapy has a mechanistically coherent basis for use in alopecia areata (T cell-mediated immune privilege collapse), and this is supported by a substantial body of retrospective cohort data, multiple clinical studies, systematic reviews, and a completed Phase 4 trial (NCT01167946). The evidence is sufficient to justify clinical consideration, but the absence of large, placebo-controlled RCTs and the Philippines regulatory gap require structured safeguards before wider adoption.

To proceed, the following is needed:

Philippines regulatory verification: Confirm whether methylprednisolone is marketed locally under any brand or hospital formulary listing via direct FDA Philippines enquiry
Package insert and safety data: Obtain and review the full prescribing information to complete S1 safety screening (currently a blocking data gap)
Mechanism of action documentation: Retrieve full DrugBank MOA entry for methylprednisolone to strengthen the mechanistic rationale section
Clinician validation: Confirm clinical feasibility with a dermatologist or clinical pharmacist experienced in AA management in the Philippines context
Relapse monitoring protocol: Any application of methylprednisolone pulse in AA should include a defined relapse-monitoring plan, as high relapse rates post-treatment are well-documented (see PMID 25872976)
Special population assessment: Paediatric dosing considerations require separate review (PMID 36461625) before any paediatric application
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.